Skip to main content
. Author manuscript; available in PMC: 2014 Feb 1.
Published in final edited form as: World J Urol. 2012 Apr 22;32(1):185–191. doi: 10.1007/s00345-012-0869-2

Figure 2.

Figure 2

Net benefit curves for the PCPTHG (solid black line) versus the rules of biopsying all men (dashed line) and no men (dotted horizontal line at 0). A risk tool has clinical benefit when a specific risk threshold (x-axis) is used for referral to biopsy when its net benefit curve is higher than the curves corresponding to biopsying all men or no men.